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High Frequency of p16INK4A Promoter Methylation
in NRAS-Mutated Cutaneous Melanoma
Anders Jonsson1,2, Rainer Tuominen1,2, Eva Grafstro¨m1, Johan Hansson1 and Suzanne Egyhazi1
The p16INK4A tumor suppressor is often deleted, or otherwise inactivated, in malignant melanoma. To investigate
the loss of p16INK4A in greater detail, we analyzed 77 cutaneous melanoma metastases. Of these 56 retained at
least one p16INK4A allele, and 21 had biallelic deletions. Using methylation-specific PCR, direct sequencing,
and immunohistochemical methods, we analyzed p16INK4A promoter methylation, mutations, and protein
expression, respectively. In addition, 14 corresponding primary tumors were analyzed for protein expression.
Results were compared to clinicopathological parameters and previously obtained data regarding mutations in
proto-oncogenes NRAS and BRAF. Results revealed that p16INK4A promoter methylation was present in 15 of
59 (25%) metastases; nonsynonymous mutations in 9 of 56 (16%) metastases; and protein expression in 12 of
67 (18%) metastases. Protein expression was lost during progression from primary to metastatic tumors, 71%
(10 of 14) and 43% (6 of 14) being positive, respectively. However, the genetic and epigenetic alterations of
p16INK4A observed could not explain the lack of p16INK4A protein in 27 metastases, indicating the presence of
additional inactivating mechanisms for p16INK4A. Interestingly, p16INK4A promoter methylation was significantly
overrepresented in NRAS-mutated samples compared to NRAS wild-type samples (P¼ 0.0004), indicating an
association between these two events.
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INTRODUCTION
Cutaneous malignant melanoma (CMM) is a skin cancer with
a poor prognosis at the metastatic stage (stage III–IV), and the
disease shows a pronounced increase in incidence through-
out Caucasian populations. The genetic and epigenetic
aberrations known to be related to the development of
CMM include inactivation of the CDKN2A gene by deletion,
mutation, or promoter methylation (Serrano et al., 1997; Ruas
and Peters, 1998; Dahl and Guldberg, 2007). The CDKN2A
gene has two alternative reading frames resulting in two
unrelated tumor suppressor proteins, p16INK4A and p14ARF,
which are associated with the tumor suppressive functions of
the RB protein and the p53 protein, respectively (Serrano
et al., 1997; Lowe and Sherr, 2003; Ha et al., 2007).
Mutations in CDKN2A are found both as somatic events in
tumors, and rarely as germ-line alterations in the hereditary
situation. Germ-line mutations, occur in approximately
25–40% of melanoma families (Hussussian et al., 1994;
Kamb et al., 1994; Curtin et al., 2005; Chin et al., 2006). In
Sweden,o10% of the familial melanoma kindreds are found
to carry germ-line mutations of CDKN2A (Platz et al., 1997).
Somatic genetic aberrations in CDKN2A are dominated by
deletions (30–60%) (Flores et al., 1996; Funk et al., 1998).
In addition, CMM etiology very commonly involves
constitutive activation of the RAS–RAF–MEK–ERK signal
transduction pathway, leading to enhanced proliferation
and survival of tumor cells. In total, 70–90% of CMM
metastases carry mutations in one of the proto-oncogenes
BRAF or NRAS (Omholt et al., 2003; Haluska et al., 2006).
However, prolonged oncogenic stimuli may also trigger
cellular senescence through induction of p16INK4A and
p53 proteins (Serrano et al., 1997; Narita et al., 2003;
Michaloglou et al., 2005). Thus, avoiding cell-cycle arrest and
senescence during melanoma development possibly necessi-
tates inactivation of CDKN2A, which influences both the
p16INK4A and p53 pathways. This is an attractive explanation as
to why CDKN2A is so frequently inactivated in melanoma.
Previously, we have screened for mutations in NRAS (exon 2)
and BRAF (exons 11 and 15) in CMM metastases (Omholt
et al., 2003; Edlundh-Rose et al., 2006). We have also
previously characterized the prevalence of allelic losses of
CDKN2A in these tumors (Grafstrom et al., 2005). We found
that samples with bi- or monoallelic deletions in the INK4
region (containing the CDKN2A and CDKN2B genes, which
code for the tumor suppressor proteins p16INK4A, p14ARF, and
p15, respectively) had shorter median overall survival
compared to patients without deletions. However, patients
with tumors with biallelic deletions had the same overall
survival as those with tumors with monoallelic deletions. This
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could be due to other mechanisms of gene inactivation in
tumors that carry monoallelic deletions such as promoter
methylation or mutations.
This study was aimed at investigating the prevalence of
sporadic mutations and transcriptional silencing of p16INK4A
by promoter methylation, in CMM metastases with mono-
allelic deletions and metastases without deletions in
p16INK4A. Furthermore, we wished to relate inactivation of
p16INK4A to clinical and pathological parameters and the
previously studied NRAS and BRAF oncogene mutation status
in these metastases. To obtain a more complete picture of
p16INK4A aberrations in melanoma metastases, we also
included tumors with biallelic deletions.
RESULTS
p16INK4A promoter methylation
Promoter methylation of p16INK4A was observed in 15 of 59
(25%) metastases using methylation-specific PCR (MSP)
(Figure 1, Table 1). Three of the tumors with biallelic
deletions have been analyzed and none of them showed
any promoter methylation, as expected because both alleles
have been lost. Assuming that none of the tumors with
biallelic deletions have any promoter methylation, p16INK4A
promoter methylation occurred in 19% (15 of 77) of this
cohort. Promoter methylation among tumors without p16INK4
deletions was similar to those with monoallelic deletions, 7 of
21 (33%) and 8 of 35 (23%), respectively (P¼0.53).
p16INK4A mutation screening
Sequencing of CDKN2A exons 1a, 2, and 3 revealed that 9 of 56
(16%) metastases carried mutations in the coding region of
p16INK4A (Table 1). Assuming that none of the tumors with
biallelic deletions carry any mutation, 12% (9 of 77) of this
cohort carried CDKN2A mutations. All CDKN2A mutations
were heterozygous except in the M69 case that was hemi/
homozygous. Interestingly, one metastasis (sample M12) had
three different p16INK4Amutations (two nonsynonymous and one
synonymous). A summary of all observed genetic variants found
is shown in Supplementary Table S3 online. The two tandem
mutations and four of the single-nucleotide substitutions showed
classical UVB mutation signature patterns, i.e. G:C4A:T
transitions at dipyrimidine sites, and GG:CC4AA:TT tandem
alterations (Hocker and Tsao, 2007), indicating that several of
the p16INK4A mutations were caused by UV exposure.
Promoter methylation and p16INK4A mutation rarely
coexisted—only sample M01 had both.
Expression of the p16INK4A protein
A majority of the metastases lacked p16INK4A protein
expression, including all those with p16INK4A promoter
methylation (Table 1). In total, only 12 of 67 (18%)
metastases were p16INK4A positive. As expected, none of
the 11 analyzed tumors with biallelic deletions were
p16INK4A positive. Assuming that all the tumors with biallelic
deletions lack p16INK4A protein expression, 16% (12 of 77) of
our cohort was p16INK4A positive. There were 7 of 21 (33%)
p16-positive tumors without p16INK4A deletions, compared to
5 of 35 (14%) tumors with monoallelic deletions (P¼0.11).
In three cases only cytoplasmic staining was observed.
Interestingly, three p16INK4A-positive metastases (samples
M12, M50, and M69) were also found to carry both a
mutation in the coding region of p16INK4A and a monoallelic
deletion. However, all samples with truncating mutations
(i.e., p.E33X, p.Q50X, p.R80X, and p.W110X) and the tumor
with a microdeletion causing a frameshift reading and
truncated translation (p.A67fs145X) were negative for stain-
ing with the monoclonal p16INK4A antibody.
Furthermore, immunohistochemistry (IHC) analysis of the
14 primary tumors revealed that a majority of these expressed
p16INK4A (10 of 14 positive, i.e. 71%) and that expression was
lost in some of their corresponding metastases (6 of 14
positive, i.e. 43%) (Figure 2, Table 1). The primary tumors
showed a more heterogeneous staining pattern for p16INK4A
compared to the metastases, with negative areas (nests or
clones) within the tumor. Unexpectedly, two cases negative
for p16INK4A expression in the primary tumors were positive
in the corresponding metastases (samples M24 and M66). An
explanation could be that these primary tumors metastasized
before they lost p16INK4A expression or that the metastases
originated from minor p16INK4A-positive clones within the
primary tumors.
The number of p16INK4A positive tumors was significantly
higher among tumors without any genetic or epigenetic
alterations in comparison to tumors with one or two
alterations, 7 of 11 (64%) and 5 of 56 (9%), respectively
(P¼0.0002). Noteworthy, 27 of 55 (49%) p16INK4A protein-
expression-negative metastases had at least one intact
p16INK4A allele (Table 1).
Correlation of different p16INK4A aberrations with NRAS and
BRAF oncogene mutation status
Interestingly, p16INK4A promoter methylation predominantly
occurred in NRAS-mutated tumors with 12 of 15 (80%)
methylated tumors carrying NRAS mutation (Table 1). Pro-
moter methylation has been found in 12 of 23 (52%) NRAS-
mutated metastases, 2 of 27 (7%) BRAF-mutated metastases,
and 1 of 9 (11%) wild-type (WT) metastases (Table 2). The
proportion of samples with p16INK4A promoter methylation
among NRAS-mutated samples was significantly higher than
the proportion in those with WT NRAS (P¼ 0.0004).
This is in contrast to samples with p16INK4A mutations,
which seemed to be more frequent in BRAF-mutated
M21
LWtMUWtMUWtMULWtMUWtMULWtMUL
H2O–CT505M01M38
Figure 1. Representative gel images from the methylation-specific PCR
(MSP) analyses. L¼100 bp DNA ladder, U/M/Wt¼ PCR products from the
PCR specific for unmethylated, methylated, and non-CT converted-specific
MSP reactions, respectively. Samples were M21, M38, and M01, and control
reactions for the MSP were the methylation-positive cell line 505, Wt-positive
CT-converted control DNA (-CT), and non-template control for PCR (H2O).
CT, bisulfite conversion of cytosine to thymidine.
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Table 1. Clinical and pathological characterization of the subjects in the study with data from the analyses of
p16INK4A
ID
Age at
diagnosis
(years) Sex
Histopathological
subtype
Breslow
thickness
(mm)
Oncogene
mutated
p16INK4A
deletion
p16INK4A
promoter
methylation
p16INK4A/
p14ARF
mutation
p16INK4A protein
metastasis (nuclear/
cytoplasmic), primary tumor
[nuclear/cytoplasmic]
M01 53 M SSM 1.5 BRAF No Methyl p.L63P (0/0)
M02 58 F SSM 0.9 BRAF No Unmethyl p.A67fs145X/
p.A123fs212X
(0/0)
M03 35 F SSM 0.5 BRAF No Unmethyl p.Q50X (0/0)
M04 51 F SSM 6 BRAF No Unmethyl p.R80X/p.P135L (0/0)
M05 42 F SSM 2.2 BRAF No Unmethyl No (0/0)
M06 70 M NM 8 BRAF No Unmethyl No (0/0)
M07 82 M SSM 3.1 BRAF No Unmethyl No (0/2)
M08 91 M NM 13 BRAF No Unmethyl No (0/3)
M09 79 M Unkn NA BRAF No Unmethyl No (2/3)
M10 71 M SSM 0.5 BRAF Mono Methyl No (0/0)
M11 46 M NM 3 BRAF Mono Unmethyl p.E33X (0/0)
M12 36 M SSM 3.2 BRAF Mono Unmethyl p.G23S, p.L97P (2/2) [3/3]
M13 69 F UC 3.5 BRAF Mono Unmethyl No (0/0) [0/0]
M14 62 M SSM 1.6 BRAF Mono Unmethyl No (0/0) [3/3]
M15 49 M Unkn NA BRAF Mono Unmethyl No (0/0)
M16 40 M SSM 1.2 BRAF Mono Unmethyl No (0/0)
M17 41 F SSM 1.9 BRAF Mono Unmethyl No (0/0)
M18 50 M Unkn NA BRAF Mono Unmethyl No (0/0)
M19 71 M UC 7 BRAF Mono Unmethyl No (0/0)
M20 68 F UC 3 BRAF Mono Unmethyl No (0/0)
M21 84 F SSM 1.6 BRAF Mono Unmethyl No (0/0)
M22 78 F UC 0.7 BRAF Mono Unmethyl No (0/0)
M23 34 F Unkn NA BRAF Mono Unmethyl No (0/0)
M24 45 F NM 1.4 BRAF Mono Unmethyl No (1/2) [0/0]
M25 57 F ALM 0.8 BRAF Mono Unmethyl No (1/2)
M26 40 F SSM 4.8 BRAF Bi Unmethyl ND (0/0)
M27 80 M UC 3 BRAF Bi Unmethyl ND (0/0)
M28 54 M SSM 2.7 BRAF Bi ND ND ND
M29 72 F SSM 0.4 BRAF Bi ND ND ND
M30 93 M NM 7.1 BRAF Bi ND ND ND
M31 24 F SSM 0.3 BRAF Bi ND ND ND
M32 78 M NM 1.2 BRAF Bi ND ND (0/0)
M33 59 F NM 1.1 BRAF Bi ND ND ND
M34 29 M SSM 1 BRAF Bi ND ND ND
M35 72 M SSM 2.5 NRAS No Methyl No (0/0) [0/1]
M36 58 M NM 4.3 NRAS No Methyl No (0/0) [0/2]
M37 76 F Unkn NA NRAS No Methyl No (0/0)
M38 65 M Unkn NA NRAS No Methyl No (0/0)
M39 72 F NM 2.4 NRAS No Methyl No (0/0)
M40 79 M UC NA NRAS No Methyl No (0/0)
Table 1 continued on the following page
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metastases (6 of 25, 24%) compared to NRAS-mutated (2 of
23, 9%) and WT metastases (1 of 8, 12%) although this
difference was not statistically significant (P¼0.27) (Table 2).
However, the NRAS or BRAF mutation status shows little
difference in the degree of inactivation of p16INK4A at the
protein level (Table 2).
Table 1. Continued
ID
Age at
diagnosis
(years) Sex
Histopathological
subtype
Breslow
thickness
(mm)
Oncogene
mutated
p16INK4A
deletion
p16INK4A
promoter
methylation
p16INK4A/
p14ARF
mutation
p16INK4A protein
metastasis (nuclear/
cytoplasmic), primary tumor
[nuclear/cytoplasmic]
M41 75 F NM 1.4 NRAS No Unmethyl No (0/0)
M42 77 F NM 2.5 NRAS No Unmethyl No (1/1) [3/3]
M43 24 F SSM 1.4 NRAS No Unmethyl No (1/1)
M44 75 M SSM 5.3 NRAS Mono Methyl No (0/0) [0/0]
M45 85 M NM 9 NRAS Mono Methyl No (0/0) [0/1]
M46 34 F NM 3.8 NRAS Mono Methyl No (0/0) [3/2]
M47 50 M NM 3.5 NRAS Mono Methyl No (0/0)
M48 79 F NM 5.1 NRAS Mono Methyl No (0/0)
M49 84 F NM 2.7 NRAS Mono Methyl No (0/0)
M50 53 F SSM 1.1 NRAS Mono Unmethyl p.P70L (2/3) [2/2]
M51 86 F UC 0.9 NRAS Mono Unmethyl p.W110X/p.G166R (0/0)
M52 69 M SSM 1.6 NRAS Mono Unmethyl No (0/0) [2/3]
M53 54 F UC 0.8 NRAS Mono Unmethyl No (0/0)
M54 71 M SSM 1.3 NRAS Mono Unmethyl No (0/0)
M55 69 M NM 5 NRAS Mono Unmethyl No (0/0)
M56 68 M SSM 3 NRAS Mono Unmethyl No (0/0)
M57 65 M Unkn NA NRAS Mono Unmethyl No (0/0)
M58 44 M SSM 3.5 NRAS Bi ND ND (0/0)
M59 81 M SSM 4.4 NRAS Bi ND ND ND
M60 45 F SSM 1.8 NRAS Bi ND ND ND
M61 53 M NM 5 NRAS Bi ND ND (0/0)
M62 73 M NM 10.5 NRAS Bi ND ND (0/0)
M63 50 M UC 8 NRAS Bi ND ND ND
M64 68 F UC 1 NRAS Bi ND ND ND
M65 47 F SSM 0.7 No No Unmethyl No (0/0)
M66 81 M SSM 2.1 No No Unmethyl No (1/1) [0/0]
M67 65 M ALM 10 No No Unmethyl No (1/2) [3/3]
M68 70 F SSM 2.6 No Mono Methyl No (0/0)
M69 58 M LMM 0.5 No Mono Unmethyl p.F90L/p.L145P (0/1)
M70 40 F NM 7 No Mono Unmethyl No (0/0)
M71 65 M NM 10 No Mono Unmethyl No (0/0)
M72 65 F UC 3.5 No Mono Unmethyl No (0/0)
M73 89 M SSM 8.5 No Bi Unmethyl ND (0/0)
M74 77 F ALM 30 No Bi ND ND (0/0)
M75 49 F SSM 0.7 No Bi ND ND (0/0)
M76 47 M NM 2.6 No Bi ND ND (0/0)
M77 68 F NM 6 No Bi ND ND (0/0)
Abbreviations: ALM, acral lentigious melanoma; LMM, lentigo maligna melanoma; NA, not available; ND, not determined; NM, nodular melanoma;
No, no mutation/deletion; SSM, superficial spreading melanoma; UC, unclassifiable; Unkn, patient with unknown primary tumor.
The boldface entries in the column for p16INK4A/p14ARF mutation are related to P16INK4A, and the non-bold entries next to the bold entries are related to P14ARF.
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Correlation of different p16INK4A aberrations with
clinicopathological parameters
None of the clinicopathological parameters analyzed (gen-
der, age at diagnosis, histopathological type, and Breslow
thickness) showed any significant association with p16INK4A
biallelic deletion, promoter methylation, mutation, or protein
expression (data not shown). However, patients with tumors
with CDKN2A mutations tended to have an earlier onset
(median age, 53 years) than those lacking CDKN2A muta-
tions (median age, 69 years) (P¼0.053).
DISCUSSION
In this study, we analyzed p16INK4A promoter methylation,
mutation, and protein expression in tumors either lacking
p16INK4A deletions or having monoallelic or biallelic dele-
tions. Although the smallest deletions are difficult to detect
and to correctly assign the tumors in their respective deletion
categories, we consider that the data presented in this work is
accurate enough to give a good picture of the total impact of
p16INK4A aberrations in melanoma metastases. The major
obstacles of performing high-quality analyzes on excised
a b
c d
e f
g h
Figure 2. Images of p16INK4A immunohistochemistry (IHC) sections. Panels show the metastases M42 and M46 and their corresponding primary tumors:
(a) primary M46, negative control; (b) primary M46, anti-p16INK4A; (c) metastasis M46, negative control; (d) metastasis M46, anti-p16INK4A; (e) primary M42,
negative control; (f) primary M42, anti-p16INK4A; (g) metastasis M42, negative control; (h) metastasis M42, anti-p16INK4A. Both primary tumors and metastasis
M42 were regarded positive for p16INK4A expression and M46 metastasis was regarded negative. Bar¼ 100mm.
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tumor material are the presence of nontumor cells in the
samples, degradation of DNA in archival tumor tissues
and during the bisulfite treatment, and the cellular hetero-
geneity within the tumors. For these reasons, the included
tumors and sections were selected so as to have high
percentages of tumor cells (470%), the PCR reactions were
designed to be compatible with moderately degraded DNA,
and evaluation of IHC sections was performed for multiple
regions.
We found that p16INK4A promoter methylation occurred in
19% of the metastases (including the tumors with biallelic
deletions), which is similar to previous studies, reporting
between 5 and 19% in primary melanomas and 27 and 33%
in metastases (Straume et al., 2002; Sharpless and Chin,
2003; Freedberg et al., 2008). There was a somewhat higher
proportion of methylated samples among tumors without
p16INK4A deletions (33% methylated) compared to those with
monoallelic deletions (23% methylated), but this difference
was not statistically significant. Our results indicate that
monoallelic deletions and promoter methylation are not
mutually excluding events, and both alterations contribute to
p16INK4A inactivation. However, all samples with promoter
methylation were negative for p16INK4A protein, suggesting
that both alleles are silenced, although this has to be
confirmed using allele-specific methylation analyses.
An interesting finding was that 52% (12 of 23) of the
NRAS-mutated tumors had p16INK4A promoter methylation
compared to only 7% (2 of 27) of the BRAF-mutated tumors.
The preferential coexistence of p16INK4A promoter methyla-
tion and NRASmutation in the same tumors may be related to
a cooperation of these genetic changes. Despite that tumors
with NRAS or BRAF mutations show little difference in the
degree of inactivation of p16INK4A at the protein level (88 vs.
79% inactivation, respectively) and both oncogene mutations
are known to induce senescence in melanocytes (Narita
et al., 2003; Michaloglou et al., 2005), the sequence of events
leading to neoplastic development may be different. The
senescence inducing effect of NRAS mutation may be more
pronounced and faster, thereby necessitating rapid (or
preexisting) inactivation of p16INK4A whereas BRAF muta-
tions might coexist with a functional p16INK4A protein early in
the tumor development.
Another possible explanation for the differential existence
of promoter methylation and NRAS mutation compared to
methylation and BRAF mutation could be presence of a
mechanistic link between establishment of the NRAS muta-
tion and the events leading to aberrant promoter methylation
of p16INK4A. Support for such a link is that the transcription
factor E2F, downstream of ras, has been shown to influence
DNA methyltransferase 1 activity in a mouse model (Kimura
et al., 2003). In addition, H-ras transformation has been
shown to be accompanied by increased levels of DNA
methyltransferase activity and repression of several genes by
methylation. Treatment of 5-aza-deoxycytidine or suppres-
sion of oncogenic ras led to reexpression of these genes
showing that oncogenic ras activity is linked to epigenetic
silencing (Lund et al., 2006).
Overall, 12% (including the tumors with biallelic dele-
tions) of our samples carried p16INK4A mutations, which is
similar to previous reports (around 8%) on cutaneous
melanoma (Hocker and Tsao, 2007; Freedberg et al., 2008).
In malignant melanoma, the majority of somatic mutations in
CDKN2A have been shown to exhibit UVR signature (Hocker
and Tsao, 2007). Several of the p16INK4A mutations observed
in this study were C4T or CC4TT transitions, typically
caused by UVB exposure.
In several studies, it has been found that p16INK4A protein
expression is gradually lost during melanoma progression:
almost all benign nevi are positive for p16INK4A (74–100%),
whereas primary melanomas show reduced levels of
p16INK4A expression (28–78% p16 positive) and, in metas-
tases, only 6–24% of samples are p16INK4A positive (Ghiorzo
et al., 2004a; Mihic-Probst et al., 2006; Fearfield et al., 2007;
Sanki et al., 2007). Our results are in line with other reports
on p16INK4A expression. In our study 16% of the metastases
(including tumors with biallelic deletions) expressed p16INK4A
protein. Three of these had both a monoallelic deletion and
carried a mutation in the coding region. We and others have
found that p16INK4A mutation-positive tumors express the
protein although it has been shown that some of these point
mutations impair the function of p16INK4A protein (Ghiorzo
et al., 2004b; Scaini et al., 2009). In addition (Yang et al.,
2005) predicted the effects of 117 reported CDKN2A point
mutations showing large variations regarding the impact on
p16INK4A protein.
Table 2. Summary of the alterations of p16INK4A in
relation to NRAS and BRAF oncogene mutation status
Total (n=77) BRAF (n=34) NRAS (n=30) WT (n=13)
p16INK4A deletion
No 21 (27%) 9 (26.5%) 9 (30%) 3 (23%)
Mono 35 (45%) 16 (47%) 14 (47%) 5 (38.5%)
Bi 21 (27%) 9 (26.5%) 7 (23%) 5 (38.5%)
p16INK4A promoter methylation*
No 44 (75%) 25 (93%) 11 (48%) 8 (89%)
Yes 15 (25%) 2 (7%) 12 (52%) 1 (11%)
ND 18 7 7 4
p16INK4A/p14ARF mutation
No 47 (84%) 19 (76%) 21 (91%) 7 (88%)
Yes 9 (16%) 6 (24%) 2 (9%) 1 (12%)
ND 21 9 7 5
p16INK4A protein expression
No 55 (82%) 22 (79%) 23 (88%) 10 (77%)
Yes 12 (18%) 6 (21%) 3 (12%) 3 (23%)
ND 12 6 6 0
Abbreviation: ND, not determined.
*P=0.0004.
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However, lack of expression of p16INK4A protein in 49% of
the samples with at least one functional gene copy could not
be fully explained by the genetic and epigenetic alterations
identified in our study. The reasons for this could be
misclassification of tumors with biallelic deletions into
(primarily) the monoallelic deletion group in particular if
tumors with deletions spanning only few kilobases are
common. This is unlikely because pattern of deletion
mapping suggest that small deletions are uncommon
(Gonzalgo et al., 1997; Palmieri et al., 2000).
Other means of inactivation might also take place in these
samples—for example, repressors of p16INK4A and other
epigenetic events apart from promoter methylation. One such
mechanism might be transcriptional repression by b-catenin
(Delmas et al., 2007). Constitutive activation of the Wnt/b-
catenin pathway is common in melanoma, and Delmas et al.
(2007) reported that activated b-catenin in cooperation with
activated N-ras promotes melanoma development in mice.
Posttranscriptional micro-RNA-mediated suppression of
p16INK4A translation by miR-24 has also been reported (Lal
et al., 2008).
In summary, we have characterized mechanisms and
patterns of p16INK4A inactivation in human melanoma. In our
study p16INK4A is most commonly inactivated by deletions
and/or promoter methylation (Table 2). Although the analysis
of CDKN2A is limited by the lack of study of p14ARF,
we found that four of nine mutations in exon 2 also affect the
p14ARF protein (Table 1). In addition, we have previously
shown that p14ARF is lost in 67% of the cases with p16INK4A
biallelic deletions and that p14ARF biallelic deletions
rarely occur without simultaneous loss of p16INK4A (Graf-
strom et al., 2005). We found interesting patterns regarding
inactivation of p16INK4A in melanoma metastases, in relation
to NRAS and BRAF oncogene mutation status—possibly
reflecting genetic and epigenetic alterations that occur during
melanoma development and progression. Intriguingly,
p16INK4A promoter methylation predominantly occurred in
NRAS-mutant cases indicating an association between the
two events.
MATERIALS AND METHODS
Patients and tumor samples
A total of 77 melanoma metastases, including 21 with biallelic
deletions, from equal number of melanoma patients who underwent
surgery between 1992 and 2002 at the Karolinska University
Hospital were included in the study. Both formalin-fixed, paraffin-
embedded archival samples and fresh-frozen tissue samples were
used for DNA extraction. In addition, 14 corresponding primary
tumors were available for analysis of p16INK4A protein expression.
Approval has been obtained from the ethics committee of Karolinska
Institutet. Patients have given informed consent. The study has been
conducted according to the Declaration of Helsinki Principles.
Patient characteristics with clinical and pathological parameters are
summarized in Supplementary Table S1 online and given in Table 1
for the individual cases.
The relative allelic concentrations of p16INK4A in intron 1
(immediately 50 of exon 2) had been analyzed previously by
quantitative real-time RT-PCR (Grafstrom et al., 2005).
DNA extraction
DNA was extracted from two to four 10-mm-thick slices of formalin-
fixed, paraffin-embedded tissue using the QIAamp DNA Mini kit
(Qiagen, Hilden, Germany), according to the manufacturer’s
instructions. DNA was also extracted from frozen tissue samples in
10 cases, using the same kit.
Methylation-specific PCR
After bisulfite treatment of DNA, promoter methylation of p16INK4A
was analyzed by MSP, using primers specific for unmethylated (U)
and methylated (M) sequences. Bisulfite conversion of DNA was
performed using the EZ DNA methylation Gold Kit (Zymo Research,
Orange, CA) following the manufacturer’s instructions. DNA
(500 ng) was used for each bisulfite conversion reaction, which
was performed at least in duplicate for each sample. The
completeness of the bisulfite conversion reaction was controlled
using non-CT converted specific PCR for all samples (WT primers)
(Herman et al., 1996). Primer sequences are given in Supplementary
Table S2 online.
Approximately 100 ng bisulfite-modified DNA was used in each
(U, M, and WT) PCR, which also contained primers (2mM per
primer); dNTPs (each 400 mM), 1 PCR buffer, 1.5mM MgCl2; 2U
of Platinum Taq polymerase (Invitrogen, Paisley, UK); and 1%
BSA (New England Biolabs, Hitchin, UK), in a reaction volume
of 20 ml. DMSO (5%; Sigma-Aldrich Sweden AB, Stockholm,
Sweden), was used in the WT mix. PCR conditions were 3minutes
at 95 1C, 36 cycles  (20 seconds at 94 1C, 15 seconds at annealing
temperature, 20 seconds at 72 1C), then 5minutes at 72 1C, and soak
at 10 1C.
In addition, a nested PCR approach was used for samples with
low initial DNA concentration. Bisulfite-converted DNA was then
amplified in a two-step PCR procedure using previously published
outer primers (Holst et al., 2003). The first PCR conditions were as
described above except reduced number of cycles (20 cycles) (30
cycles in the MSP).
PCR products were separated on 1.6% agarose gels, stained with
ethidium bromide, and visualized under UV light. A sample was
regarded positive for methylation when at least two different PCRs
from separate bisulfite conversion reactions yielded M products.
DNA from cell line A375 was used as an unmethylated control and
DNA from cell line 505 was used as a methylated control. Cell line
DNA not modified with sodium bisulfite was used as WT control,
and water replaced DNA in the contamination control reaction.
Sequencing of p16INK4A
Exons 1a, 2, and 3 of CDKN2A (p16INK4A) were PCR amplified
(primer sequences and annealing temperatures are found in
Supplementary Table S2 online). DNA extracted from frozen tissue
was amplified using primers spanning the whole exon 2, whereas
paraffin-extracted DNA was amplified in two overlapping fragments.
Approximately 100 ng DNA was used in each PCR as follows:
3minutes at 95 1C, 40 cycles  (20 seconds at 94 1C, 20 seconds at
annealing temperature, 20 seconds at 72 1C), then 5minutes at 72 1C,
and soak at 12 1C. Samples that yielded low amounts of PCR
products were amplified further in a nested PCR. PCR products (2ml)
from the first reaction were then amplified for additional 24 cycles.
All PCR products were enzymatically treated with shrimp alkaline
phosphatase and exonuclease I (50minutes at 37 1C, followed by
www.jidonline.org 2815
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20minutes at 80 1C). Bidirectional sequencing was performed using
the Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA) and same primers as for PCR. Products
were sequenced on an automated sequencer (ABI3130XL; Applied
Biosystems). To confirm mutations, we reamplified samples and
sequenced them again.
Immunohistochemistry
IHC was performed on 4mm, formalin-fixed, paraffin-embedded
sections. Heat-induced antigen retrieval was performed in Reveal
solution in a decloaking chamber (Biocare, Concord, CA) according
to the manufacturer’s instructions, and thereafter rinsed in hot rinse.
Briefly, sections were incubated overnight (4 1C) with the mono-
clonal primary p16INK4A antibody, clone JC8 (Biocare) diluted 1:250
in Tris-buffered saline buffer with 1.5% horse serum. Negative
controls were incubated without primary antibody. Secondary
antibody incubation using streptavidin/peroxidase complex was
according to a kit manual (Vectastain Universal Quick Kit; Vector
Laboratories, Burlingame, CA) as was development with 3,30-
diaminobenzidine (Immunkemi, Stockholm, Sweden). Finally, sec-
tions were counterstained with Mayer’s hematoxylin. Normal breast
tissue and a melanoma tumor positive for p16INK4A were included in
all IHC batches.
Independent evaluation of all slides was first performed by three
observers (AJ, SE, and EG), thereafter a consensus was reached
regarding the p16INK4A protein expression. The intensity was scored
(0¼ absent, 1¼weak, 2¼moderate, 3¼ strong staining) for nuclear
and cytoplasmic staining. Samples scored 1 or higher were
considered positive. Samples witho5% positive cells were regarded
negative (score¼ 0).
Statistical methods
Statistical tests were two-sided and P-values exceeding 95%
confidence level were considered significant (t-test, w2-test, or
Fisher’s exact test when appropriate).
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